United Kingdom (UK)
Recombinant monoclonal antibody to Entry-fusion complex associated protein OPG095. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma M12B9.
UniProt Accession Number of Target Protein: P07612
Alternative Name(s) of Target: L1; L1R; VACV; Protein L1; OPG099; VACWR088; Virion membrane protein M25; EFC-associated protein OPG095
Immunogen: The original antibody was raised by immunizing a BALB/c mouse with live VACV and refolded L1 protein.
Specificity: This antibody is specific for the L1 protein of the vaccina virus. Regions 25-34 and 113-131 of L1 are part of the epitope.
Application Notes: A chimeric scFv-Fc version of this antibody was used for an ELISA on recombinant protein L1 of the variola virus strain India-1967, on lysate of MV and EV forms of the vaccinia virus strain LIVP (RU2790134C1), and on overlapping linear biotinylated peptides (Kaever et al., 2014; PMID:25031354). The ability of this antibody to protect mice in vivo from VACV challenge was tested on BALB/c mice. The mice were injected with the antibody a day before they were infected with VACV-WR. The antibody is able to prevent death in mice, but it is not able to prevent weight loss (Matho et al., 2015; PMID:26325270). This antibody was used for a FACS based neutralization assay. Here Vero E6 cells were incubated with a mixture of antibody and VACV-GFP and then tested in flow cytometry (Kaever et al., 2014; PMID:25031354). This antibody was used for in vivo treatment of mice infected with VACV. It was shown that injection of this antibody after being infected with the virus lead to a 100% survival rate (Zaitseva et al., 2017; PMID:28495463).
Antibody first published in:
Keaver et al. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein J Virol. 2014 Oct;88(19):11339-55. PMID:25031354
Note on publication:
The original paper generated five murine anti-L1 monoclonal antibodies (MAbs), which clustered into 3 distinct epitope groups. To further understand the protective mechanism of the anti-L1 antibodies.